Li Kang Biomedical Co., Ltd. (TPEX:6242)
Taiwan · Delayed Price · Currency is TWD 34.00
0.00 (0.00%)
Aug 19, 2026, 9:59 AM CST
Li Kang Biomedical Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 573.36 | 589.21 | 565.52 | 629.38 | 684.25 | 386.97 |
Revenue Growth | -2.92% | 4.19% | -10.15% | -8.02% | 76.82% | -15.27% |
Gross Profit Gross Profit Growth | 385.44 | 398.25 | 386.1 | 426.15 | 388.58 | 264.68 |
Operating Income Operating Income Growth | 87.19 | 98.28 | 90.02 | 133.37 | 137.36 | 57.25 |
Net Income Net Income Growth | 76.39 | 83.82 | 77.02 | 110.99 | 112.09 | 51.44 |
Earnings Per Share EPS Growth | 2.38 | 2.62 | 2.47 | 4.12 | 4.16 | 1.91 |
EPS Growth | -11.31% | 6.07% | -40.05% | -0.96% | 117.46% | -25.49% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 178.22 | 190.22 | 454.4 | 301.02 | 263.43 | 175.75 |
Total Debt Total Debt Growth | 126.56 | 126.02 | 91.92 | 90.84 | - | 33.47 |
Net Cash (Debt) Net Cash Growth | 51.66 | 64.2 | 362.48 | 210.19 | 263.43 | 142.28 |
Net Cash Growth | -82.18% | -82.29% | 72.46% | -20.21% | 85.15% | -20.78% |
Net Cash Per Share Net Cash Per Share Growth | 1.61 | 2.01 | 11.62 | 7.80 | 9.77 | 5.28 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 76.31 | 92.15 | 65.38 | 96.74 | 157.24 | 60.45 |
Capital Expenditures CapEx Growth | -253.74 | -329.38 | -62.75 | -3.26 | -1.16 | -4.25 |
Free Cash Flow Free Cash Flow Growth | -177.43 | -237.23 | 2.63 | 93.48 | 156.08 | 56.19 |
Free Cash Flow Growth | - | - | -97.19% | -40.11% | 177.77% | -29.67% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 67.22% | 67.59% | 68.27% | 67.71% | 56.79% | 68.40% |
Operating Margin | 15.21% | 16.68% | 15.92% | 21.19% | 20.07% | 14.79% |
Pretax Margin | 16.32% | 17.66% | 17.54% | 22.11% | 20.58% | 16.40% |
Profit Margin | 13.32% | 14.23% | 13.62% | 17.64% | 16.38% | 13.29% |
FCF Margin | -30.95% | -40.26% | 0.46% | 14.85% | 22.81% | 14.52% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 2.000 | 2.000 | 2.000 | 2.500 | 1.739 | 1.242 |
Dividend Per Share Growth | 0% | 0% | -20.00% | 43.75% | 40.00% | -46.43% |
Dividend Yield | 5.88% | 5.38% | 5.16% | 4.98% | 4.37% | 4.86% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.28 | 14.89 | 17.72 | 14.08 | 11.73 | 16.96 |
P/FCF Ratio | - | - | 518.62 | 16.72 | 8.42 | 15.53 |
PS Ratio | 1.89 | 2.12 | 2.41 | 2.48 | 1.92 | 2.26 |